-
Palmer misses Chelsea's Champions League clash with Atalanta
-
Trump says Europe heading in 'bad directions'
-
Benin hunts soldiers behind failed coup
-
Salah a 'disgrace' for Liverpool outburst: Carragher
-
Peace deal at risk as DR Congo, Burundi slam Rwanda and M23 advances
-
Feminists outraged at video of French first lady's outburst against activists
-
Suspect arrested in theft of Matisse artworks in Brazil: officials
-
Troubled Liverpool host Barnsley in FA Cup third round
-
Slot has 'no clue' whether rebel star Salah has played last Liverpool game
-
Liverpool boss Slot says Salah relationship not broken
-
Powerful 7.6 quake strikes off Japan, tsunami warning lifted
-
100 abducted Nigerian children handed over to state officials
-
Lula orders road map to cut fossil-fuel use in Brazil
-
EU pushes back 2035 combustion-engine ban review to Dec. 16
-
Court will give decision in Sala compensation hearing on March 30
-
Mamdani to swap humble apartment for NY mayor's mansion
-
MSF says conditions for Gaza medics 'as hard as it's ever been' despite truce
-
Sala compensation hearing opens in Cardiff's dispute with Nantes
-
Syria's Sharaa vows to promote coexistence, reconciliation one year after Assad's ousting
-
Club Brugge sack coach in build up to Arsenal clash
-
US residents get free entry to national parks on Trump's birthday
-
Spurs looking into Bissouma conduct after 'laughing gas' report
-
Machado's mother says hopes daughter will collect Nobel in person
-
Salah dropped by Liverpool for Inter Milan clash after outburst
-
Boeing closes takeover of aviation supplier Spirit
-
Salah dropped by Liverpool for Inter Milan clash
-
Brazil police ID suspect in Matisse theft
-
Deal agreed to save Frankfurt's euro sculpture
-
Inter's Thuram braced for fightback from crisis-hit Liverpool
-
Trump says to sign order blocking AI regulation by states
-
Fracturing Real Madrid need Mbappe magic in Haaland showdown
-
13 inmates die in violence-plagued Ecuador prison
-
Paramount counters Netflix with hostile bid for Warner Bros
-
European allies back Zelensky after Trump criticism
-
'One Battle After Another' leads Golden Globes noms with nine
-
Tens of thousands celebrate as Syria marks one year since Assad's ouster
-
Meta to allow European users to share less data: EU
-
Three things to watch ahead of the 2026 F1 season
-
Zelensky meets European allies after Trump criticism
-
Barcelona defence on 'another level' now, says Flick
-
AI tools help choose best embryos for IVF
-
Ex-footballer Barton handed suspended sentence for offensive posts
-
Stocks mostly rise as Fed set to cut US rates
-
Rooney says Salah 'destroying his Liverpool legacy'
-
Louvre trade unions call for rolling strike next week
-
Nigeria's cash-splashing 'Detty December' festivities kick off in Lagos
-
Syria's Sharaa calls for united efforts to rebuild a year after Assad's ouster
-
Thailand-Cambodia clashes reignite, killing soldier and civilians
-
Sri Lanka doubles troops for flood disaster recovery
-
African players in Europe: Unused sub Salah steals spotlight
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
O.Gaspar--PC